CTLA4 and IL2RA variants increase risk of autoimmune thyroid disease.

Genetic variants in the CTLA4 and IL2RA genes are well-established risk factors for a range of autoimmune conditions, with particularly strong evidence linking them to autoimmune thyroid diseases (AITD) such as Graves’ disease and Hashimoto’s thyroiditis. These genes are central to the maintenance of immune tolerance, and their variation can significantly alter how the body regulates its immune responses.

Clinical and effectiveness evidence

Large-scale genetic studies and meta-analyses have consistently identified specific polymorphisms in these genes as susceptibility markers:

• CTLA4 variants: The CTLA4 +49A/G (rs231775) and CT60 (rs3087243) variants are among the most frequently cited risk factors. For instance, the G allele of the +49A/G polymorphism has been shown in meta-analyses of over 12,000 subjects to significantly increase the risk for Graves’ disease (OR = 1.48; 95% CI: 1.34–1.64) and Hashimoto’s thyroiditis (OR = 1.29; 95% CI: 1.14–1.46).
• IL2RA variants: Polymorphisms such as rs2104286 are strongly associated with Graves’ disease. Genome-wide association studies (GWAS) have reported significant risk increases (OR = 1.25; 95% CI: 1.18–1.32, p = 7.9 × 10⁻¹⁵) associated with this locus.
• Broad autoimmunity: Beyond the thyroid, these variants contribute to a "shared genetic architecture" for multiple conditions, including Type 1 Diabetes, Rheumatoid Arthritis, and Multiple Sclerosis.

Mechanistic explanations

The increased susceptibility stems from the roles these genes play in controlling T-cell activity:

• Checkpoint failure (CTLA4): The CTLA-4 protein acts as an "off switch" for T-cells by competing with the activating receptor CD28. Risk variants in CTLA4 lead to reduced expression of the protein or decreased mRNA stability. This impairs the inhibitory signal, allowing autoreactive T-cells to proliferate and attack thyroid tissue, leading to the production of anti-TPO and anti-TG antibodies.
• Regulatory T-cell dysfunction (IL2RA): The IL2RA gene encodes CD25, a critical component of the IL-2 receptor. This receptor is essential for the health and function of regulatory T-cells (Tregs), which normally suppress auto-immune attacks. Risk variants can reduce CD25 expression or interfere with IL-2 signaling (e.g., via reduced STAT5 phosphorylation). This weakens the Treg "braking" system, enabling self-reactive T-cells to escape regulation.

Bottom line

Genetic variants in CTLA4 and IL2RA significantly increase susceptibility to autoimmune thyroid disease by impairing the body’s natural immune checkpoints and regulatory T-cell functions. These findings underscore the importance of T-cell regulation pathways in the development of AITD and other common autoimmune conditions.